{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P07288",
      "entity_text" : "prostate-specific antigen",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-1224" ],
      "Organ" : [ "uberon:UBERON:0000104" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "The primary endpoint for efficacy was a 50% reduction in the prostate specific antigen (PSA) level.",
  "reading_complete" : "2020-08-04T14:21:51Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T14:21:10Z",
  "trigger" : "level",
  "evidence" : [ "prostate-specific antigen (PSA) level" ],
  "pmc_id" : "5503969",
  "score" : 0
}